Paul Wallace, MD
Dermatology · Beverly Hills, CANPI 1063494474
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $277,375 of the $387,626 with a category attached, or 71.6%. 31 manufacturers reported payments, led by UCB, Inc. at 33.2% of the total. Reporting peaked in 2019 at $168,996 and has fallen 52.8% since, to $79,840 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 754 payments — averaging $514.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$129K
- AbbVie$108K
- Novartis$74K
- Bristol Myers Squibb$36K
- Amgen$28K
- Arcutis Biotherapeutics, Inc.$9K
- plus $5K from 25 others
Across 481 payments — averaging $13,987 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.1M
- AbbVie$1.3M
- Pfizer$957K
- Amgen$910K
- Janssen Research & Development, LLC$681K
- E.r. Squibb & Sons, L.L.C.$292K
- plus $483K from 6 others
What the payments were for
- Consulting fees$53,33514%
- Speaking & faculty fees$277,37572%
- Travel & lodging$40,95011%
- Food & beverage$15,8724%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 220 | $128,881 |
| AbbVie | 169 | $107,565 |
| Novartis | 100 | $74,212 |
| Bristol Myers Squibb | 36 | $36,009 |
| Amgen | 41 | $27,627 |
| Arcutis Biotherapeutics, Inc. | 18 | $8,608 |
| Sun Pharmaceutical Industries Inc. | 16 | $533 |
| Johnson & Johnson | 22 | $523 |
| LEO Pharma AS | 1 | $450 |
| Dermavant Sciences, Inc. | 10 | $432 |
| Sanofi | 17 | $428 |
| Pfizer | 30 | $419 |
| Lilly USA, LLC | 13 | $350 |
| E.r. Squibb & Sons, L.L.C. | 17 | $268 |
| Botanix SB Inc | 3 | $179 |
| Galderma Laboratories, L.p. | 8 | $155 |
| Incyte Corporation | 6 | $139 |
| LEO Pharma Inc. | 6 | $138 |
| Janssen Research & Development, LLC | 1 | $125 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 2 | $70 |
| Genentech USA, Inc. | 3 | $68 |
| Almirall LLC | 2 | $55 |
| DUSA Pharmaceuticals, Inc. | 2 | $52 |
| Verrica Pharmaceuticals Inc. | 2 | $48 |
| Dermira, Inc. | 2 | $46 |
| Organon | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $26 |
| Mayne Pharma Commercial LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$387,626 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 16 | $323,742 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 41 | $290,933 |
| OdomzoSonidegib Phosphate | 12 | $162,286 |
| Dupixent PenDupilumab | 36 | $132,717 |
| ZoryveRoflumilast | 73 | $66,047 |
| VtamaTapinarof | 20 | $27,001 |
| OpzeluraRuxolitinib Phosphate | 14 | $26,728 |
| Clobetasol Propionate | 101 | $4,330 |
| Clindamycin Phosphate | 39 | $2,980 |
| Tretinoin | 32 | $2,653 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 44 | $2,334 |
| Triamcinolone Acetonide | 190 | $2,115 |
| Ketoconazole | 99 | $1,495 |
| CiclopiroxCiclopirox Olamine | 38 | $1,477 |
| Metronidazole | 21 | $995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Arcutis Biotherapeutics, Inc.Zoryve | $8,608 | $66,04773 claims |
| Dermavant Sciences, Inc.Vtama | $432 | $27,00120 claims |
| Incyte CorporationOpzelura | $139 | $26,72814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.
Other dermatology in Beverly Hills
- Jacquiline HabashyBeverly Hills$143K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.